Loading...
The survival benefit of neoadjuvant chemotherapy and pCR among patients with advanced stage triple negative breast cancer
Triple negative breast cancer (TNBC) is an aggressive subtype that accounts for 15-20% of cases, with a higher incidence of relapse/death. Even with adjuvant chemotherapy, the 5 year distant metastasis-free survival rate remains low. A total of 452 tumor registry patients with TNBC and no evidence o...
Na minha lista:
| Udgivet i: | Oncotarget |
|---|---|
| Main Authors: | , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Impact Journals LLC
2017
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5762543/ https://ncbi.nlm.nih.gov/pubmed/29348858 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.22521 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|